2018-11-12T15:38:03-06:00 2018-06-30 410746749 CLIFTONLARSONALLEN LLP 1301 W 22ND ST STE 1100 OAK BROOK IL 60523 990 2017-07-01 731386920 GATEWAY FOR CANCER RESEARCH GATE 8473427450 500 EAST REMINGTON ROAD SCHAUMBURG IL 60173 TERESA HALL BARTELS PRESIDENT 5473427450 2018-11-02 1 THOMAS G ANDREWS P00095596 6305738600 2018-11-02 67.137.57.251 2018-11-02 15:47:55 CD P 4352940A9571D7C5DDA6B43C112B0F5A28A64F72 2EEED599B99E77CDBDF45BEBFA9D7EF6A807E359 2017 2019-02-21 02:37:17Z TERESA HALL BARTELS 500 EAST REMINGTON ROAD SCHAUMBURG IL 60173 8605782 0 X GATEWAYCR.ORG X 1991 OK TO FIND AND FUND CLINICAL CANCER RESEARCH. 24 24 0 0 0 0 5379869 3736215 0 0 312137 445437 237720 0 5929726 4181652 6587640 6097050 0 0 0 0 0 0 0 133377 119960 6721017 6217010 -791291 -2035358 14620509 13859712 9033018 9897276 5587491 3962436 X TO FUND MEANINGFUL AND BREAKTHROUGH CLINICAL TRIALS WORLDWIDE THAT HELP PEOPLE LIVING WITH CANCER TO FEEL BETTER, LIVE LONGER AND CONQUER CANCER TODAY! 0 0 6159349 6097050 GATEWAY FOR CANCER RESEARCH (FORMERLY KNOWN AS CANCER TREATMENT RESEARCH FOUNDATION OR CTRF), A NON-PROFIT 501(C)(3) ORGANIZATION, WAS ESTABLISHED IN 1991 TO PROMOTE RESEARCH THROUGH THE TREATMENT PROCESS AND SUPPORT PROGRESSIVE MOLECULAR, NUTRITIONAL AND IMMUNOLOGICAL RESEARCH PROGRAMS THAT MORE TRADITIONAL CANCER RESEARCH INSTITUTIONS MAY NOT FUND. GATEWAY IS DEDICATED TO ADVANCING INNOVATIONS IN THE SCIENTIFIC COMMUNITY AND SPEEDING THEM TO THE CANCER PATIENT'S BEDSIDE. THE WORK OF GATEWAY IS ABOUT GIVING CANCER PATIENTS THE ABILITY TO LIVE LONGER, MORE FULFILLING AND HEALTHIER LIVES.NO PORTION OF ANY PUBLIC CONTRIBUTION TO GATEWAY GOES TO FUNDRAISING OR ADMINISTRATIVE SALARIES. DUE TO GENEROUS CORPORATE UNDERWRITING OF ADMINISTRATIVE EXPENSES, 99% OF PUBLIC CONTRIBUTIONS RECEIVED ARE APPLIED DIRECTLY TO SUPPORT AGGRESSIVE CANCER RESEARCH AND SCIENTIFIC DEVELOPMENT PROGRAMS. OUR BOARD OF SCIENTIFIC COUNSELORS APPLIES STRINGENT GUIDELINES FOR REVIEWING EACH GRANT APPLICATION, RECOMMENDING TO THE BOARD OF DIRECTORS ONLY THOSE THAT ARE IN KEEPING WITH THE FOUNDATION'S MISSION. THROUGH THIS FORMAL REVIEW PROCESS, GATEWAY ENSURES THAT FUNDING IS GRANTED STRICTLY TO THOSE PROJECTS THAT ARE TRULY INNOVATIVE AND HAVE THE POTENTIAL TO QUICKLY TRANSLATE FROM THE RESEARCHER'S LABORATORY TO THE PATIENT'S BEDSIDE.AS THE NATION'S SECOND MOST DEADLY AND COSTLY DISEASE, CANCER RECOGNIZES NO BOUNDARIES. IN THE BATTLE AGAINST CANCER, GATEWAY IS ON THE FRONTLINES, SUPPORTING CLINICAL RESEARCH INITIATIVES DESIGNED TO ENHANCE QUALITY OF LIFE FOR CANCER PATIENTS, SURVIVORS, AND FAMILIES IN EVERY COMMUNITY NATIONWIDE. GATEWAY FOR CANCER RESEARCH HAS FUNDED OVER 168 STUDIES AND IS CURRENTLY FUNDING 57 STUDIES DEALING WITH NEW AGENT STUDIES, IMMUNOLOGY, NUTRITION, AND GENE THERAPY. BECAUSE WE ARE VIGILANT ABOUT MONITORING OUR CLINICAL RESEARCH STUDIES, WE CAN ASSURE OUR FUNDING PARTNERS THE BEST UTILIZATION OF THEIR CONTRIBUTIONS. WE IDENTIFY AND ENCOURAGE GREATER INTERACTION WITH OUR RESEARCHERS AND ENCOURAGE APPLICATIONS FROM CLINICAL INVESTIGATORS WHO CONSISTENTLY PROVIDE US WITH IMPORTANT PATIENT IMPACT RESEARCH.HISTORICAL DOCUMENTATION OF OUR RESEARCH PROJECTS PROVIDES A WINDOW THROUGH WHICH WE CAN VIEW OUR PAST ACCOMPLISHMENTS AND IMPLEMENT NEW STRATEGIC PROGRAMS THAT REFLECT OUR MISSION - TO FUND MEANINGFUL AND BREAKTHROUGH CLINICAL TRIALS WORLDWIDE THAT HELP PEOPLE LIVING WITH CANCER TO FEEL BETTER, LIVE LONGER AND CONQUER CANCER TODAY! 6159349 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 1 1 0 0 1 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 1 39 0 0 0 0 0 0 0 1 1 0 0 0 0 X 24 24 1 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 0 0 0 AZ CA CO CT FL IL ME MD MA MI MN MT MO NH NJ NY NC OH OK PA RI SC TN TX VA WA WI X X DIANE KINSLER 8473427450 500 EAST REMINGTON RD SCHAUMBURG IL 60173 X JANICE ANDERSON TREASURER 0.30 X X 0 0 0 VIRGINIA AHERIN DIRECTOR 0.30 X 0 0 0 FRED DEGRANDIS DIRECTOR 0.30 X 0 0 0 JOE CALTABIANO DIRECTOR 0.30 X 0 0 0 DENIZ RAZON DIRECTOR 0.30 X 0 0 0 JAKE GOLDSTEIN DIRECTOR 0.30 X 0 0 0 RICHARD J STEPHENSON CHAIRMAN 0.30 X X 0 0 0 HARLAN TELLER VICE CHAIRMAN 0.30 X X 0 0 0 RHONDA KOKOT SECRETARY 0.30 X X 0 0 0 MARY LOU SMITH DIRECTOR 0.30 X 0 0 0 J TERRY SIMMONS DIRECTOR 0.30 X 0 0 0 KENNETH MONARREZ DIRECTOR 0.30 X 0 0 0 HEATHER KANE DIRECTOR 0.30 X 0 0 0 EDWIN ROBERSON DIRECTOR 0.30 X 0 0 0 CHRISTOPHER SURDENIK DIRECTOR 0.30 X 0 0 0 EVA KMIECIC DIRECTOR 0.30 X 0 0 0 JENNIFER STEPHENSON KELLER DIRECTOR 0.30 X 0 0 0 TONY FESTA DIRECTOR 0.30 X 0 0 0 DAN GARMS DIRECTOR 0.30 X 0 0 0 STACIE J STEPHENSON DIRECTOR 0.30 X 0 0 0 STEVEN DELCO DIRECTOR 0.30 X 0 0 0 CHRIS DOLEMAN DIRECTOR 0.30 X 0 0 0 MARGARET LAMANNA DIRECTOR 0.30 X 0 0 0 SATISH TADIKONDA DIRECTOR 0.30 X 0 0 0 TERESA HALL BARTELS EX-OFFICIO, PRESIDENT 40.00 X 0 0 0 0 0 0 0 0 0 0 0 59071 3017131 660013 3736215 461239 461239 4126215 4142017 -15802 -15802 -15802 282113 3017131 282113 0 4181652 0 0 445437 5670450 5670450 426600 426600 8500 8500 BOARD OF SCIENTIFIC COU 51199 51199 BANK AND CREDIT CARD FE 49161 49161 MISCELLANEOUS 11100 11100 6217010 6159349 57661 0 2042754 490724 1526191 1147873 111319 51579 74698 113000 10767655 11933126 97892 123410 14620509 13859712 9018358 9887276 14660 10000 9033018 9897276 X 5545596 3955134 41895 7302 5587491 3962436 14620509 13859712 X -2035358 -150220 560523 X X 0 1 X 1 0 X 3243122 3036651 3013245 5643089 3736215 18672322 3243122 3036651 3013245 5643089 3736215 18672322 1022040 17650282 226903 352043 433285 372615 461239 1846085 20518407 7272409 0.86020 0.87130 X 0 X 9624331 -150220 4758763 560523 282113 5451179 4173152 8500 8500 4181652 11249386 4758763 282113 5040876 6208510 8500 8500 6217010 PART X, LINE 2: THE FOUNDATION EVALUATES ITS EXPOSURE FOR UNCERTAIN TAX POSITIONS ON AN ANNUAL BASIS. AS OF JUNE 30, 2018 AND 2017, THERE WERE NO LIABILITIES RELATED TO UNCERTAIN TAX POSITIONS. PART XI, LINE 2D - OTHER ADJUSTMENTS: SPECIAL EVENT EXPENSES NETTED WITH FUNDS GENERATED 282,113. PART XI, LINE 4B - OTHER ADJUSTMENTS: INVESTMENT MANAGEMENT FEES 8,500. PART XII, LINE 2D - OTHER ADJUSTMENTS: SPECIAL EVENT EXPENSES NETTED WITH FUNDS GENERATED 282,113. PART XII, LINE 4B - OTHER ADJUSTMENTS: INVESTMENT MANAGEMENT FEES 8,500. SCHEDULE D, PARTS XII AND XIII, LINES 2D AMOUNTS REPRESENT DIRECT EXPENSES FOR SPECIAL EVENTS HELD AND ARE REFLECTED IN PART VIII ON LINE 8B AGAINST REVENUES FROM FUNDRAISING EVENTS. 1 EUROPE (INCLUDING ICELAND & GREENLAND) 0 0 GRANTS TO RECIPIENTS LOCATED IN REGION GRANTS FOR CANCER RESEARCH 325000 NORTH AMERICA 0 0 GRANTS TO RECIPIENTS LOCATED IN REGION GRANTS FOR CANCER RESEARCH 101600 0 0 0 0 0 0 426600 0 426600 EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM CANCER RESEARCH 50000 CASH EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM CANCER RESEARCH 50000 CASH NORTH AMERICA CANCER RESEARCH 101600 CASH EUROPE (INCLUDING ICELAND & GREENLAND) CANCER RESEARCH 225000 CASH 4 0 0 0 0 0 0 0 PART I, LINE 2: PROCEDURES ARE THE SAME AS DOMESTIC GRANTS. SEE SCHEDULE I. GALA 2838625 2652408 186217 186217 VINO CON STELL 338800 303483 35317 35317 1 121819 61240 60579 60579 3299244 3017131 282113 282113 282113 0 1 CHILDREN'S HOSPITAL LOS ANGELES 4650 WEST SUNSET BOULEVARD MS 54 LOS ANGELES CA 90027 951690977 501(C)(3) 300000 CANCER RESEARCH MEMORIAL SLOAN-KETTERING CANCER CENTER 1275 YORK AVENUE NEW YORK NY 10065 131624182 501(C)(3) 50000 CANCER RESEARCH JOHNS HOPKINS UNIVERSITY 1650 ORLEANS STREET CRB1 4M10 BALTIMORE MD 21287 520595110 501(C)(3) 370747 CANCER RESEARCH ST JUDE CHILDREN'S HOSPITAL 262 DANNY THOMAS PLACE MEMPHIS TN 38103 620646012 501(C)(3) 206013 CANCER RESEARCH MD ANDERSON CANCER CENTER 1515 HOLCOMBE BLVD UNIT 0462 HOUSTON TX 77030 174601118 501(C)(3) 736163 CANCER RESEARCH COLUMBIA UNIVERSITY 1130 ST NICHOLAS AVENUE ROOM 601A NEW YORK NY 10032 135598093 501(C)(3) 243292 CANCER RESEARCH UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER 6001 FOREST PARK DRIVE DALLAS TX 75390 756002868 501(C)(3) 222307 CANCER RESEARCH RUTGERS THE STATE UNIVERSITY OF NEW JERSEY 195 LITTLE ALBANY ST NEW BRUNSWICK NJ 08903 146235411 501(C)(3) 500000 CANCER RESEARCH DANA FARBER CANCER INSTITUTE 450 BROOKLINE AVENUE BOSTON MA 02215 042263040 501(C)(3) 687592 CANCER RESEARCH THE WISTAR INSTITUTE 3601 SPRUCE STREET PHILADELPHIA PA 19104 236434390 501(C)(3) 250000 CANCER RESEARCH UNIVERSITY OF ALABAMA AT BIRMINGHAM 1720 2ND AVENUE SOUTH FOT 1060 BIRMINGHAM AL 35294 636005396 501(C)(3) 300000 CANCER RESEARCH JOHN THEURER CANCER CENTER AT HACKENSACK UNIVERSITY 92 2ND STREET HACKENSACK NJ 07601 221487576 501(C)(3) 331137 CANCER RESEARCH MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER 55 FRUIT STREET BOSTON MA 02114 041564655 501(C)(3) 510793 CANCER RESEARCH UNIVERSITY OF IOWA HOSPITALS AND CLINICS 200 HAWKINS DRIVE IOWA CITY IA 52242 237436761 501(C)(3) 229084 CANCER RESEARCH CLEVELAND CLINIC FOUNDATION 1422 EUCLID AVENUE SUITE 1300 CLEVELAND OH 44115 340714585 501(C)(3) 450136 CANCER RESEARCH RUTGERS CANCER INSTITUTE 195 LITTLE ALBANY ST NEW BRUNSWICK NJ 08903 462354111 501(C)(3) 283186 CANCER RESEARCH 16 0 PART I, LINE 2: ALL GRANT APPLICATIONS MUST GO THROUGH A RIGOROUS PEER REVIEW PROCESS LED BY OUR BOARD OF SCIENTIFIC COUNSELORS - A DISTINGUISHED BOARD OF RENOWNED SCIENTISTS, PHYSICIANS, RESEARCHERS AND PATIENTS. THROUGH THIS PROCESS, SCIENTISTS INCLUDING EXPERTS IN A PARTICULAR AREA OF CANCER REVIEW AND EVALUATE APPLICATIONS AGAINST A CAREFULLY PRESCRIBED SET OF CRITERIA FOR JUDGING THE SCIENTIFIC MERIT AND POTENTIAL VALUE OF EACH PROPOSED STUDY. THIS REVIEW, NOT ONLY INCLUDES A NUMERICAL GRADING OF OBJECTIVE CRITERIA, IT ALSO INCLUDES A SUBJECTIVE COMMENTARY WITH SUGGESTED MODIFICATIONS. UPON RECOMMENDATION BY THE BOARD OF SCIENTIFIC COUNSELORS, THE APPLICATION IS SUBMITTED TO GATEWAY'S BOARD OF DIRECTORS FOR FUNDING CONSIDERATION. IF APPROVED AND FUNDED, GATEWAY GRANTEES SUBMIT REGULAR REPORTS (I.E., SEMI-ANNUALLY) TO THE RESEARCH GRANTS DEPARTMENT THAT SUMMARIZE THE PROGRESS OF THE FUNDED TRIAL ACCORDING TO THE PRINCIPAL INVESTIGATOR'S PROPOSED TIMELINE AND MILESTONES. ANNUALLY, THE RESEARCH GRANTS TEAM REVIEWS ALL REPORTS SUBMITTED WITHIN THE PAST YEAR AND ASSESSES WHETHER GRANTS ARE "ON TRACK OR "OFF TRACK", WITH RESPECT TO PATIENT ACCRUALS, TIMELY REPORTING, AND PROGRESS TOWARD MEETING STUDY MILESTONES. WHEN NEEDED, THE RESEARCH GRANTS TEAM CONSULTS WITH THE BOARD OF SCIENTIFIC COUNSELORS TO REVIEW AND DEVELOP RECOMMENDATIONS FOR THE BOARD OF DIRECTORS ABOUT THOSE GRANTS THAT THEY DEEM "OFF TRACK". FUNDING CONTINUATION DECISIONS ARE CONTINGENT UPON GOOD PROGRESS/SPENDING. FORM 990, PART VI, SECTION A, LINE 2 BOARD MEMBERS RICHARD J STEPHENSON AND STACIE STEPHENSON ARE SPOUSES. BOARD MEMBERS RICHARD J STEPHENSON AND JENNIFER STEPHENSON KELLER ARE FATHER AND DAUGHTER, RESPECTIVELY. BOARD MEMBERS RICHARD J STEPHENSON AND FRED DEGRANDIS ARE ALSO BOARD MEMBERS OF CANCER TREATMENT CENTERS OF AMERICA. FORM 990, PART VI, SECTION B, LINE 11B FORM 990 IS FIRST REVIEWED BY THE ORGANIZATION'S INTERNAL STAFF AND A SUBSEQUENT REVIEW BY EXECUTIVE STAFF. THE FORM 990 IS THEN REVIEWED BY THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS AND SENT TO EACH CURRENT MEMBER OF THE BOARD FOR THEIR REVIEW AND ACTION. FORM 990, PART VI, SECTION B, LINE 12C THE ORGANIZATION'S BOARD MEMBERS AND STAFF ARE REQUIRED TO REVIEW THE CONFLICT OF INTEREST POLICY DURING A REGULARLY SCHEDULED BOARD MEETING AND DURING THE STAFF MEMBERS ANNUAL PERFORMANCE EVALUATION MEETING. FORM 990, PART VI, SECTION C, LINE 19 THE FOUNDATION MAKES ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC VIA IT'S WEBSITE AND OTHER NONPROFIT PUBLICATIONS. FORM 990, PART XI, LINE 9: RETURN OF UNUSED GRANT FUNDS 560,523. FORM 990, PART XII, LINE 2C THE ORGANIZATION'S BOARD OF DIRECTORS ASSUMES RESPONSIBILITY FOR OVERSIGHT OF THE AUDIT OF ITS FINANCIAL STATEMENTS AND SELECTION OF AN INDEPENDENT ACCOUNTANT. THIS PROCESS HAS NOT CHANGED FROM THE PRIOR YEAR.